相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma
Jon J. Hiles et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2008)
Metastatic renal cell carcinoma: recent advances and current therapeutic options
Andres Jan Schrader et al.
ANTI-CANCER DRUGS (2008)
Cancer statistics, 2008
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2008)
Tyrosine kinase inhibitors in clinical practice: Patient selection
Jean-Jacques Patard
EUROPEAN UROLOGY SUPPLEMENTS (2008)
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Sorafenib for Older Patients With Renal Cell Carcinoma: Subset Analysis From a Randomized Trial
Tim Eisen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Continuous daily dosing of sunitinib in patients with metastatic renal cell cancer
Lauren Harshman et al.
ONKOLOGIE (2008)
Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis - Results of a randomized controlled trial
Sylvie Negrier et al.
CANCER (2007)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer
Ronald M. Bukowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer
Jared A. Gollob et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis
R. M. Bukowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
New challenges in kidney cancer therapy: sunitinib
H. Izzedine et al.
ANNALS OF ONCOLOGY (2007)
Managing side effects of angiogenesis inhibitors in renal cell carcinoma
Viktor Gruenwald et al.
ONKOLOGIE (2007)
Advanced renal cell carcinoma - current and emerging management strategies
Bernard Escudier
DRUGS (2007)
Sunitinib in patients with metastatic renal cell carcinoma
Robert J. Motzer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
S Faivre et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase II placebo-controlled randomized discontinuation trial of sorafnib in patients with metastatic renal cell carcinoma
Mark J. Ratain et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
New treatment approaches in metastatic renal cell carcinoma
Andrea Mancuso et al.
CURRENT OPINION IN UROLOGY (2006)
Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab
FA Scappaticci et al.
JOURNAL OF SURGICAL ONCOLOGY (2005)
Addition of bevacizurnab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial
FF Kabbinavar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma
BI Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
DF McDermott et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma
TM Mekhail et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma
MB Atkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Genetic basis of cancer of the kidney: Disease specific approaches to therapy
WM Linehan et al.
CLINICAL CANCER RESEARCH (2004)
Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan-Kettering Cancer Center experience
RJ Motzer et al.
CLINICAL CANCER RESEARCH (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer
JC Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
JC Yang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer
HW Herr et al.
JOURNAL OF UROLOGY (2002)
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer
RC Flanigan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma
AJ Pantuck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial
GHJ Mickisch et al.
LANCET (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Activation of HIF1α ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex
T Kamura et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
